Recovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building
RISE
Developing a Telehealth Intervention for Alcohol and Trauma Among LGBTQ+ People
1 other identifier
interventional
80
1 country
1
Brief Summary
This is a two-part study to develop and test a brief, virtual therapy program for lesbian, gay, bisexual, transgender, and queer (LGBTQ+) people who have experienced trauma and use alcohol. Phase 1: You'll be invited to share your perspective to help make the program relevant, inclusive, and affirming. Phase 2: You may have the opportunity to try the adapted program by receiving free virtual therapy with LGBTQ+-affirming therapists.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 12, 2025
CompletedFirst Posted
Study publicly available on registry
October 16, 2025
CompletedStudy Start
First participant enrolled
November 30, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2028
December 9, 2025
December 1, 2025
11 months
August 12, 2025
December 1, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Posttraumatic Stress Disorder Diagnosis and Severity using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Posttraumatic Stress Disorder (PTSD) will be assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), a clinician-administered interview that evaluates Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) PTSD criteria. It provides both a total severity score (0-80) and a dichotomous diagnosis (present/absent). Units of Measure: Total score (0-80); diagnosis status (yes/no)
Baseline: Past 30 days 1-week Follow-up: Past 1 week
Posttraumatic Stress Disorder Symptom Severity using the PTSD Checklist for DSM-5 (PCL-5)
Posttraumatic Stress Disorder (PTSD) symptom severity will be assessed using the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure. Items are rated on a 5-point Likert scale from 0 ("Not at all") to 4 ("Extremely"), with a total score range of 0-80; higher scores indicate greater PTSD symptom severity. A score of 33 or higher suggests probable PTSD. Units of Measure: Total score (0-80).
Baseline: Past 30 days 1-week Follow-up: Past 1 week
Hazardous drinking levels
Structured Clinical Interview for DSM-5 - Substance Use Disorders Module (SCID-5-SUD) Description: Structured Clinical Interview for DSM-5 - Substance Use Disorders Module (SCID-5-SUD) will be used to assess the presence and severity of substance use disorders (SUDs). The SCID-5-SUD is a semi-structured clinical interview administered by trained personnel to determine whether a participant meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for a substance use disorder (e.g., alcohol, cannabis, opioids, stimulants). For each substance, the SCID-5-SUD evaluates 11 diagnostic criteria, including impaired control, social impairment, risky use, and pharmacological indicators. Severity is categorized based on the number of criteria endorsed: mild (2-3), moderate (4-5), or severe (6 or more). Units of Measure: Dichotomous diagnosis status (yes/no); severity level (mild, moderate, severe) if applicable
Baseline: Past 3 months 1-week Follow-up: Past 1 week
Change in average weekly drinking quantity
The Timeline Followback (TLFB) method will be used to assess daily alcohol consumption over the past 30 days. Participants report the number of standard drinks consumed each day, using a calendar-assisted structured interview format. Data are used to calculate total number of drinking days, total drinks consumed, average drinks per drinking day, and number of heavy drinking days (4+ drinks for women, 5+ for men). This measure provides a reliable estimate of recent alcohol use patterns and is widely used in clinical and research settings. Units of Measure: Number of drinking days, total drinks, drinks per drinking day,
Baseline: Past 30 days 1-week Follow-up: Past 1 week
Change in heavy drinking frequency
Description: Alcohol use will be assessed using a six-item self-report measure evaluating past-week drinking frequency, quantity, and risky use. Items include: frequency of drinking (scored 0-6), maximum number of drinks in 24 hours (scored 1-10), typical number of drinks per drinking day (scored 1-10), total number of drinks per week (scored 1-11), and frequency of binge drinking (defined as 4 or more drinks in one occasion) and high-intensity drinking (defined as 8 or more drinks in one occasion), both scored 0-6. In addition, the Timeline Followback (TLFB) method will be used to assess daily alcohol use over the past 30 days. The TLFB captures number of drinking days, total number of drinks, average drinks per drinking day, and number of heavy drinking days. Units of Measure: Item scores range 0-6, 1-10, or 1-11; TLFB outcomes include days and number of drinks.
Baseline: Past 30 days 1-week Follow-up: Past 1 week
Secondary Outcomes (26)
Depression symptoms
Baseline: Past 1 week 1-week Follow-up: Past 1 week
Anxiety symptoms
Baseline: Past 1 week 1-week Follow-up: Past 1 week
Perceived Stress
Baseline: Past 30 days 1-week Follow-up: Past 1 week
Suicidality
Baseline: Past 30 days 1-week Follow-up: Past 1 week
Readiness to change
Baseline: At baseline assessment 1-week Follow-up: At 1-week follow-up assessment
- +21 more secondary outcomes
Study Arms (2)
RISE
EXPERIMENTALDescription: Participants receive the RISE intervention, a remotely delivered CBT + Expressive Writing program. Intervention: Behavioral: RISE (CBT + Expressive Writing)
Control: Wait-List Control
OTHERParticipants are placed on a wait-list and offered the RISE intervention after the study period.
Interventions
This study will test a remotely delivered intervention combining Cognitive Behavioral Therapy (CBT) and Expressive Writing (EW) to address unhealthy alcohol use and traumatic stress among sexual minority women (SMW; e.g., lesbian, bisexual women) and transgender and gender-diverse (TGD) individuals. The intervention, called Recovery through Inhibitory Learning, Self-Efficacy Building, Problem-Solving, and Community Building (RISE), integrates CBT modules on assertiveness, problem-solving in high-risk situations, and building social connections with a brief EW program tailored to SMW and TGD participants. Four modules from the Unified Protocol (UP), a transdiagnostic CBT approach, will be adapted: (1) psychoeducation, goal setting, and motivational enhancement; (2) mindful emotional awareness; (3) cognitive flexibility; and (4) countering emotion-driven behaviors.
Participants assigned to the wait-list will not receive active treatment during the study period but will be offered the RISE intervention afterward.
Eligibility Criteria
You may qualify if:
- Aim 1: Providers
- Aim 2: Sexual Minority Women and Transgender and Gender Diverse Individuals
- Reporting current mental health treatment ≥1 day/month
- Receiving Cognitive Behavioral Therapy (CBT) in the past 3 months (note: participants are not ineligible if they seek concomitant care after enrollment)
- Reporting current alcohol or drug use disorder treatment, except mutual self-help (e.g., Alcoholics Anonymous) or current PTSD/trauma-focused treatment
- Need for alcohol detoxification, defined as score ≥15 on the adapted self-report Clinical Institute Withdrawal Assessment for Alcohol - Revised (CIWA-Ar)
- Active psychosis, defined as score ≥1 on the psychosis subscale of the Behavior and Symptom Identification Scale - Revised (BASIS-R)
- Active mania, defined as score ≥6 on the Altman Self-Rating Mania Scale (ASRM)
- Active suicidality, defined as score ≥22 on the Suicidal Ideation Attributes Scale (SIDAS)
- Currently legally mandated to attend treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Rhode Islandlead
- Rhode Island Foundationcollaborator
Study Sites (1)
University of Rhode Island
Providence, Rhode Island, 02860, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
August 12, 2025
First Posted
October 16, 2025
Study Start
November 30, 2025
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
September 1, 2028
Last Updated
December 9, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share
Data from this study will not be shared due to the sensitive nature of the information collected and the pilot status of the project. Additionally, data sharing is not required by the study's funder.